GLENMARK — Glenmark Pharmaceuticals Balance Sheet
0.000.00%
- IN₹475.06bn
- IN₹482.40bn
- IN₹133.22bn
- 44
- 12
- 87
- 46
Annual balance sheet for Glenmark Pharmaceuticals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | C2023 March 31st | 2024 March 31st | 2025 March 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | IAS | IAS | IAS | IAS | — |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 11,381 | 14,105 | 11,592 | 16,583 | 17,382 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 34,152 | 39,359 | 44,884 | 29,990 | 33,419 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 73,596 | 82,823 | 84,236 | 74,281 | 92,955 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 41,756 | 46,117 | 41,951 | 35,375 | 38,614 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 156,036 | 170,833 | 193,717 | 143,586 | 160,496 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 42,010 | 46,894 | 45,462 | 58,186 | 59,670 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 85,390 | 79,966 | 98,978 | 65,107 | 72,001 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 70,646 | 90,866 | 94,739 | 78,479 | 88,494 |
Total Liabilities & Shareholders' Equity | 156,036 | 170,833 | 193,717 | 143,586 | 160,496 |
Total Common Shares Outstanding |